Literature DB >> 20663891

Increased glucocorticoid receptor expression and activity mediate the LPS resistance of SPRET/EI mice.

Lien Dejager1, Iris Pinheiro, Leen Puimège, Ye-Dong Fan, Lies Gremeaux, Hugo Vankelecom, Claude Libert.   

Abstract

SPRET/Ei mice are extremely resistant to acute LPS-induced lethal inflammation when compared with C57BL/6. We found that in vivo SPRET/Ei mice exhibit strongly reduced expression levels of cytokines and chemokines. To investigate the role of the potent anti-inflammatory glucocorticoid receptor (GR) in the SPRET/Ei phenotype, mice were treated with the GR antagonist RU486 or bilateral adrenalectomy. Under such conditions, both C57BL/6 and SPRET/Ei mice were strongly sensitized to LPS, and the differences in LPS response between SPRET/Ei and C57BL/6 mice were completely gone. These results underscore the central role of GR in the LPS hyporesponsiveness of SPRET/Ei mice. Compared with C57BL/6, SPRET/Ei mice were found to express higher GR levels, which were reflected in increased GR transactivation. Using a backcross mapping strategy, we demonstrate that the high GR transcription levels are linked to the Nr3c1 (GR) locus on chromosome 18 itself. Unexpectedly, SPRET/Ei mice exhibit a basal overactivation of the hypothalamic-pituitary-adrenal axis, namely strongly increased corticosterone levels, ACTH levels, and adrenocortical size. As a consequence of the excess of circulating glucocorticoids (GCs), levels of hepatic gluconeogenic enzymes are increased, and insulin secretion from pancreatic β-cells is impaired, both of which result in hyperglycemia and glucose intolerance in SPRET/Ei mice. We conclude that SPRET/Ei mice are unique as they display an unusual combination of elevated GR expression and increased endogenous GC levels. Hence, these mice provide a new and powerful tool for the study of GR- and GC-mediated mechanisms, including immune repressive functions, neuroendocrine regulation, insulin secretion, and carbohydrate metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663891      PMCID: PMC2945598          DOI: 10.1074/jbc.M110.154484

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  79 in total

Review 1.  How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions.

Authors:  R M Sapolsky; L M Romero; A U Munck
Journal:  Endocr Rev       Date:  2000-02       Impact factor: 19.871

2.  Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells.

Authors:  Jerome Galon; Denis Franchimont; Naoki Hiroi; Gregory Frey; Antje Boettner; Monika Ehrhart-Bornstein; John J O'Shea; George P Chrousos; Stefan R Bornstein
Journal:  FASEB J       Date:  2002-01       Impact factor: 5.191

3.  Map Manager QTX, cross-platform software for genetic mapping.

Authors:  K F Manly; R H Cudmore; J M Meer
Journal:  Mamm Genome       Date:  2001-12       Impact factor: 2.957

4.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

5.  GRKO mice express an aberrant dexamethasone-binding glucocorticoid receptor, but are profoundly glucocorticoid resistant.

Authors:  T J Cole; K Myles; J F Purton; P S Brereton; N M Solomon; D I Godfrey; J W Funder
Journal:  Mol Cell Endocrinol       Date:  2001-02-28       Impact factor: 4.102

6.  Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol.

Authors:  P Putignano; A Dubini; P Toja; C Invitti; S Bonfanti; G Redaelli; D Zappulli; F Cavagnini
Journal:  Eur J Endocrinol       Date:  2001-08       Impact factor: 6.664

Review 7.  Glucocorticoid use in rheumatoid arthritis.

Authors:  Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

8.  Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock.

Authors:  H M Reichardt; T Umland; A Bauer; O Kretz; G Schütz
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 9.  Multiple sites of control of type-1 corticotropin releasing hormone receptor levels in the pituitary.

Authors:  M Nikodemova; C R Diehl; G Aguilera
Journal:  Arch Physiol Biochem       Date:  2002-04       Impact factor: 4.076

10.  Hyporesponsiveness of SPRET/Ei mice to lethal shock induced by tumor necrosis factor and implications for a TNF-based antitumor therapy.

Authors:  Jan Staelens; Ben Wielockx; Leen Puimège; Frans Van Roy; Jean-Louis Guénet; Claude Libert
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

View more
  14 in total

Review 1.  Cross-talk between HPA-axis-increased glucocorticoids and mitochondrial stress determines immune responses and clinical manifestations of patients with sepsis.

Authors:  Emiko Kasahara; Masayasu Inoue
Journal:  Redox Rep       Date:  2014-10-13       Impact factor: 4.412

Review 2.  Using the inbred mouse strain SPRET/EiJ to provide novel insights in inflammation and infection research.

Authors:  Steven Timmermans; Jolien Souffriau; Jolien Vandewalle; Lise Van Wyngene; Kelly Van Looveren; Tineke Vanderhaeghen; Claude Libert
Journal:  Mamm Genome       Date:  2018-06-09       Impact factor: 2.957

3.  Tumor necrosis factor inhibits glucocorticoid receptor function in mice: a strong signal toward lethal shock.

Authors:  Tom Van Bogaert; Sofie Vandevyver; Lien Dejager; Filip Van Hauwermeiren; Iris Pinheiro; Ioanna Petta; David Engblom; Anna Kleyman; Günther Schütz; Jan Tuckermann; Claude Libert
Journal:  J Biol Chem       Date:  2011-06-06       Impact factor: 5.157

Review 4.  Neuroimmune Regulation in Sepsis-Associated Encephalopathy: The Interaction Between the Brain and Peripheral Immunity.

Authors:  Yu-Xiao Liu; Yang Yu; Jing-Peng Liu; Wen-Jia Liu; Yang Cao; Run-Min Yan; Yong-Ming Yao
Journal:  Front Neurol       Date:  2022-06-27       Impact factor: 4.086

5.  Determining differentially expressed miRNAs and validating miRNA--target relationships using the SPRET/Ei mouse strain.

Authors:  S Timmermans; F Van Hauwermeiren; L Puimège; L Dejager; E Van Wonterghem; V Vanhooren; P Mestdagh; C Libert; R E Vandenbroucke
Journal:  Mamm Genome       Date:  2014-12-10       Impact factor: 2.957

6.  Reprogramming of glucocorticoid receptor function by hypoxia.

Authors:  Tineke Vanderhaeghen; Steven Timmermans; Deepika Watts; Ville Paakinaho; Melanie Eggermont; Jolien Vandewalle; Charlotte Wallaeys; Lise Van Wyngene; Kelly Van Looveren; Louise Nuyttens; Sylviane Dewaele; Joke Vanden Berghe; Kelly Lemeire; Joey De Backer; Laura Dirkx; Wim Vanden Berghe; Guy Caljon; Bart Ghesquière; Karolien De Bosscher; Ben Wielockx; Jorma J Palvimo; Rudi Beyaert; Claude Libert
Journal:  EMBO Rep       Date:  2021-10-26       Impact factor: 8.807

7.  Glucocorticoid Receptor Expression in Peripheral WBCs of Critically Ill Children.

Authors:  Audrey R Ogawa Shibata; Eduardo J Troster; Hector R Wong
Journal:  Pediatr Crit Care Med       Date:  2015-06       Impact factor: 3.624

8.  Glucocorticoid-induced microRNA-511 protects against TNF by down-regulating TNFR1.

Authors:  Leen Puimège; Filip Van Hauwermeiren; Sophie Steeland; Sara Van Ryckeghem; Jolien Vandewalle; Sofie Lodens; Lien Dejager; Sofie Vandevyver; Jan Staelens; Steven Timmermans; Roosmarijn E Vandenbroucke; Claude Libert
Journal:  EMBO Mol Med       Date:  2015-08       Impact factor: 12.137

9.  Comparing expression and activity of PCSK9 in SPRET/EiJ and C57BL/6J mouse strains shows lack of correlation with plasma cholesterol.

Authors:  Francine Sirois; Michel Chrétien; Majambu Mbikay
Journal:  Mol Genet Metab Rep       Date:  2016-12-10

10.  LPS resistance of SPRET/Ei mice is mediated by Gilz, encoded by the Tsc22d3 gene on the X chromosome.

Authors:  Iris Pinheiro; Lien Dejager; Ioanna Petta; Sofie Vandevyver; Leen Puimège; Tina Mahieu; Marlies Ballegeer; Filip Van Hauwermeiren; Carlo Riccardi; Marnik Vuylsteke; Claude Libert
Journal:  EMBO Mol Med       Date:  2013-03       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.